Cat. No.: HY-145405

C12-200

20 Cited Publications

Avis client

Based on 20 publication(s) in Google Scholar

C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.91%
CAS No.: 1220890-25-4
Formule: C₇₀H₁₄₅N₅O₅
Masse moléculaire:1136.93

Stockage:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

C12-200 Chemical Structure

CAS No.: 1220890-25-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vivo
Chemical Information
Publications (20)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

In Vivo

C12-200 (0.25 or 0.5 mg/kg, i.v., single injection) delivers exogenous human mRNA, producing target proteins at supraphysiological levels. Human erythropoietin (EPO) and coagulation factor IX (FIX) demonstrate potent pharmacodynamic effects in the KO mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Hemophilia B (FIX knockout (KO)) mouse model^[2]
Dosage:

0.25 or 0.5 mg/kg
Administration:

Intravenous injection (i.v.), single injection
Result:

led to plasma FIX levels of 400 ng/ml and 1.77 μg/ml with doses of 0.25 and 0.50 mg/kg, respectively, in KO mice. And C12-200 resulted in a significant increase in activity in the treated mice.

Chemical Information

CAS No. 1220890-25-4
Appearance Liquid (Density: 0.948±0.06 g/cm³)
Masse moléculaire 1136.93
Formule C₇₀H₁₄₅N₅O₅
Color Colorless to light yellow
SMILES

OC(CCCCCCCCCC)CN(CCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CCN1CCN(CCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC1
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (20)

All In Vivo ImagingRT-PCR

Sort by:

Journal Impact Factor

Nat Nanotechnol

A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis. [Abstract]

2026 Jan 14. PMID: 41535382
Immunity

Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. [Abstract]

2023 Jan 10;56(1):180-192.e11. PMID: 36563676

C12-200 purchased from MedChemExpress. Usage Cited in: Immunity. 2023 Jan 10;56(1):180-192.e11. [Abstract]

In hepatoma-bearing mice, intraperitoneal injection of liposomes to specifically deliver IL10RA siRNA to macrophages every 3 days effectively suppressed the expression of IL10RA and CD209B. For developing siRNA-loaded liposomes, a lipid mixture composed of cationic lipid C12-200, cholesterol, DSPC, and mPEG2000-DMG were dissolved in ethanol at a molar ratio of 50:38.5:10:1.5. Thereafter, the siRNA in 10 mM sodium citrate was added to the lipid mixture at a weight ratio of 1 : 7.5 and incubated at 37 ℃ for 30 min. The unentrapped siRNA was removed by ultrafiltration centrifugation. Encapsulation efficiency of the prepared liposomes was over 95%. The siRNA-loaded liposomes were used for in vivo experiments after being diluted with PBS.
Adv Mater

Simplified Lipid Nanoparticles for Tissue- And Cell-Targeted mRNA Delivery Facilitate Precision Tumor Therapy in a Lung Metastasis Mouse Model. [Abstract]

2024 Oct 10:e2409812. PMID: 39390844

C12-200 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Oct 10:e2409812. [Abstract]

The maintenance of robust luminescence in the lung was observed when the key lipid SM-102 was replaced with either C12-200 or ALC-0315.
Nat Chem

Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. [Abstract]

2024 Oct;16(10):1687-1697. PMID: 38982196
Bioact Mater

Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach. [Abstract]

2023 Dec 22:34:125-137. PMID: 38223537
J Am Chem Soc

Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing. [Abstract]

2026 Mar 11;148(9):10225-10240. PMID: 41733506
J Immunother Cancer

Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8+ T cells. [Abstract]

2024 Oct 23;12(10):e010148. PMID: 39448202
Arch Toxicol

Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model. [Abstract]

2025 Feb;99(2):755-773. PMID: 39656241
J Colloid Interface Sci

The vast majority of nucleic acid-loaded lipid nanoparticles contain cargo. [Abstract]

2024 Jun 23:674:139-144. PMID: 38925059
Proc Natl Acad Sci U S A

Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies. [Abstract]

2024 Mar 12;121(11):e2307809121. PMID: 38437543
Pharmaceutics

Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy. [Abstract]

2022 Oct 7;14(10):2129. PMID: 36297564
Int J Pharm

Plasmid DNA cationic non-viral vector complexes induce cytotoxicity-associated PD-L1 expression up-regulation in cancer cells in vitro. [Abstract]

2023 Jan 25:631:122481. PMID: 36513254
Int J Mol Sci

Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation. [Abstract]

2025 Aug 12;26(16):7774. PMID: 40869095
Eur J Pharm Biopharm

Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood. [Abstract]

2026 Jun 9:115146. PMID: 42264006
SSRN

2026 Jun 18.
Res Sq

2026 May 29.
Rowan University

2026.
bioRxiv

2025 Jun 25.
bioRxiv

Plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivo. [Abstract]

2025 Mar 1:2025.02.25.640222. PMID: 40060499
bioRxiv

Lipid Nanoparticle Composition Drives mRNA Delivery to the Placenta. [Abstract]

2022 Dec 22:2022.12.22.521490. PMID: 36597546

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (87.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (87.96 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.8796 mL

4.3978 mL

8.7956 mL

5 mM

0.1759 mL

0.8796 mL

1.7591 mL

10 mM

0.0880 mL

0.4398 mL

0.8796 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (2.20 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Khare P, et al. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells. AAPS J. 2021;24(1):8. Published 2021 Dec 6. [Content Brief]

[2]. DeRosa F, et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016;23(10):699-707. [Content Brief]

[3]. Kauffman KJ, et al. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015 Nov 11;15(11):7300-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	0.8796 mL	4.3978 mL	8.7956 mL	21.9890 mL
	5 mM	0.1759 mL	0.8796 mL	1.7591 mL	4.3978 mL
	10 mM	0.0880 mL	0.4398 mL	0.8796 mL	2.1989 mL
	15 mM	0.0586 mL	0.2932 mL	0.5864 mL	1.4659 mL
	20 mM	0.0440 mL	0.2199 mL	0.4398 mL	1.0995 mL
	25 mM	0.0352 mL	0.1759 mL	0.3518 mL	0.8796 mL
	30 mM	0.0293 mL	0.1466 mL	0.2932 mL	0.7330 mL
	40 mM	0.0220 mL	0.1099 mL	0.2199 mL	0.5497 mL
	50 mM	0.0176 mL	0.0880 mL	0.1759 mL	0.4398 mL
	60 mM	0.0147 mL	0.0733 mL	0.1466 mL	0.3665 mL
	80 mM	0.0110 mL	0.0550 mL	0.1099 mL	0.2749 mL

Keywords

C12-200

20 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

C12-200

Metabolism/Protease Compound Library

Lipid Compound Library

Coagulation and Anti-coagulation Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Liposome Library

Ionizable Lipid Compound Library

Publications Citing Use of MedChemExpress (MCE) C12-200

Activité biologique

Chemical Information

Publications (20)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

C12-200

Metabolism/Protease Compound Library

Lipid Compound Library

Coagulation and Anti-coagulation Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Liposome Library

Ionizable Lipid Compound Library

Publications Citing Use of MedChemExpress (MCE) C12-200

Activité biologique

Chemical Information

Publications (20)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

C12-200 Related Classifications

HY-145405 Related Classifications